Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — FY2016 Earnings Presentation
27 slides from Monash Ivf's earnings presentation, Aug 26, 2016
Slide 1: Monash IVF Group FY16 Results Presentation
Monash IVF Group FY16 Results Presentation 26 August 2016
Slide 2: Disclaimer
Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purpo
Slide 3: CEO Summary
CEO Summary 3 Monash IVF Group | Financial Results Presentation FY2016
Slide 4: Track record of strong financial performance
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Track record of strong financial performance Number of Patient Treatments¹ Revenue ($m) 17,901 15,861 156.6 14,287 12,582 125.0 114.0 96.3 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 3 Year CAGR3 of 12.5% 3 Year CAGR3 of 17.6%
Slide 5: FY2016 Highlights
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary FY2016 Highlights Revenues increased $31.6m (25.3%) to $156.6m vs pcp Ultrasound revenues grew >200% on pcp driven by the acquisition of Sydney Ultrasound for Women in June 2015 $156.6m $28.8m Revenue NPAT NPAT increa
Slide 6: Market growth rate will fluctuate from time to time
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Australian IVF market movement IVF Patient Treatment Growth Rates in Key Markets1 The strong FY16 IVF Patient Treatment industry 10.4% growth rates reflect a reversion to long term market trend growth rates 8.0% 7.6% Tota
Slide 7: Clinicians, Science & Innovation
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Clinicians, Science & Innovation We have a 40-year history of leadership in scientific excellence and clinical innovation We have great depth of experience in our doctors and clinical teams We established group doctor
Slide 8: Financial Highlights
Financial Highlights 8 Monash IVF Group | Financial Results Presentation FY2016
Slide 9: Profit and Loss analysis
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Profit and Loss analysis Revenues increased $31.6m (25.3%) to $156.6m vs pcp including: $m FY16 FY15 % change 10.7% from organic growth Group revenues 156.6 125.0 25.3% 14.6% derived from acquisitions EBITDA(1)(2) 49.
Slide 10: Revenue summary
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Revenue summary Revenue FY16 vs FY15 ($m) 1 Market growth: $5.8m or 4.6% increase against pcp due to 8.2% Patient Treatment growth across Australia 5 2 Market share: $3.4m or 2.7% increase as market share 160 3 4 growth con
Slide 11: Segmental earnings
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Segmental earnings Revenue Australia Revenues increased by $31.0m (26.0%) A$6.2m +$0.6m (10.7%) A$5.6m to $150.4m vs pcp driven by: Market share growth in Key Markets and NSW FY16 FY15 Reversion to trend IVF market gr
Slide 12: Cash flow highlights
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Cash flow highlights % Strong cash flow generation with $m FY16 FY15 a pre-tax conversion of operating change cash flow to EBITDA of 99.1% Net operating cash flow 44.2 36.0 22.8% (FY15: 103.3%) Cash flow from investing ac
Slide 13: Capital Management
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Capital Management Strong Balance Sheet with improved net debt to % Balance Sheet ($m) Jun 16 Jun 15 change equity ratio of 55.9% vs pcp 67.2% and enhanced ROE to 19.3% vs pcp 15.9% Cash and cash equivalents 8.5 10.0 (15.
Slide 14: Operational Highlights
Operational Highlights 14 Monash IVF Group | Financial Results Presentation FY2016
Slide 15: Australian market share - IVF
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Australian market share - IVF % Market share - IVF FY16 FY15 change MVF IVF Patient Treatment Market Share Number of Monash Group IVF Patient Key Markets Australia 14,580 13,579 7.4% Treatments1 in Monash Group’s Key Market
Slide 16: Pricing and treatment mix
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Pricing and treatment mix . Total IVF Patient Treatments increased 2,040 (12.9%) IVF Treatment numbers FY16 FY15 % change to 17,901 vs pcp. Growth in Malaysia at 19.4% Monash Group – Australia IVF Cycles and Frozen Embr
Slide 17: Expanding domestic footprint
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Expanding domestic footprint Sydney Ultrasound For Women network (11 practices across Sydney, acquired June 2015). Integration with Monash Ultrasound for Women in advanced stages Acquisitions, New Monash IVF (Bondi Junc
Slide 18: International – KL Fertility
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary International – KL Fertility Continued strong growth in volumes achieved by new Fertility Specialists in the face of a challenging local economic climate Slight EBITDA margin compression as these specialists gain tracti
Slide 19: Sydney Ultrasound for Women (SUFW)
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Sydney Ultrasound for Women (SUFW) Annual Revenue of $17.7m growing the Group revenues by 13.6% Delivered an EBITDA(1)(2) contribution of $4.0m with an EBITDA margin of 22.8% Group Ultrasound Scan volumes increased by
Slide 20: FY17 Outlook
FY17 Outlook 20 Monash IVF Group | Financial Results Presentation FY2016
Slide 21: FY17 Full year outlook
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary FY17 Full year outlook Monash IVF Group is well positioned to continue to grow its revenues and earnings in FY17 as a result of: • Strong underlying demand fundamentals for IVF and womens imaging services • Market leading s
Slide 22: Strategy FY17 and beyond
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Strategy FY17 and beyond Our strategy remains consistent and focused, to profitably grow our business through leveraging our scientific capabilities across the clinic network Science, Continue to develop industry leading
Slide 23: Summary
Summary 23 Monash IVF Group | Financial Results Presentation FY2016
Slide 24: Summary
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Summary Track record of strong long term financial performance Delivered a strong performance in FY16 with revenue growth (25.3%) and NPAT growth (34.6%) Acquisitions providing earnings growth in FY16 FY16 results i
Slide 25: Overview of Monash IVF Group
CEO Summary Financial Highlights Operational Highlights FY17 Outlook Summary Overview of Monash IVF Group Core Assisted Diagnostic and Ancillary Ultrasound Reproductive Services Services 22 clinics 2 specialised laboratories 17 clinics in Victoria and South 5 service centres Australia 15 S
Slide 26: Questions
Questions 26 Monash IVF Group | Financial Results Presentation FY2016
Slide 27: Monash IVF Group FY16 Results Presentation
Monash IVF Group FY16 Results Presentation 26 August 2016